Status:
UNKNOWN
Modified Release Posaconazole in Patients With Cystic Fibrosis
Lead Sponsor:
Bayside Health
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
A prospective single center observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once da...
Detailed Description
Use of antifungals has increased in people with cystic fibrosis. Aspergillus is the dominant fungal pathogen in this patient population and thus far, voriconazole has been used first line. Apart from ...
Eligibility Criteria
Inclusion
- Albe to provide written informed consent
- Greater than 18 years of age or older
- Have a diagnosis of cystic fibrosis
- To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus
- Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care
- Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily.
- Exclusion Criteria:
- • Known azole hypersensitivity
Exclusion
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 5 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03421366
Start Date
March 1 2018
End Date
February 5 2021
Last Update
October 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3004